N-乙酰半胱氨酸治疗COPD的临床应用研究进展  

Advances in the clinical application of N-acetylcysteine in the treatment of COPD

作　　者：贾曼 李春桃 张剑青[1] 戴路明[1] 张家强[1] 方利洲[1] 舒敬奎[1] JIA Man;LI Chuntao;ZHANG Jianqing;DAI Luming;ZHANG Jiaqiang;FANG Lizhou;SHU Jingkui(Department of Respiratory Medicine,the First Affiliated Hospital of Kunming Medical University,Kunming 650032,China)

机构地区：[1]昆明医科大学第一附属医院呼吸内二科,云南昆明650032

出　　处：《中国医药科学》2019年第3期40-43,62,共5页China Medicine And Pharmacy

摘　　要：N-乙酰半胱氨酸(NAC)是合成谷胱甘肽的前体,能够释放巯基发挥抗氧化作用,也能够溶解黏液蛋白的二硫键而作为黏液溶解剂使用。目前关于NAC治疗COPD的研究已经开展了30多年,但研究结果仍具有争议,笔者将从NAC治疗COPD的药理作用到目前的临床研究进行分析、综述,探讨NAC对COPD患者肺功能、急性加重、生活质量的作用和导致临床研究结果差异的原因。N-acetylcysteine(NAC)is a precursor to the synthesis of glutathione,its ability to release sulfhydryl groups for antioxidant action and its ability to dissolve disulfide bonds in mucoproteins for use as a mucopolytic agent. The current research on the treatment of COPD by NAC has been carried out for more than 30 years,but the results are still controversial.The author analyzes and summarizes the pharmacological effects of NAC in the treatment of COPD to the current clinical studies,and explores the effects of NAC on lung function,acute exacerbation and quality of life of COPD patients and the reasons for the differences in clinical research results.

关 键 词：氧化应激 抗炎 N-乙酰半胱氨酸 COPD 

分 类 号：R563[医药卫生—呼吸系统]